Medgenics to Host Business Update Conference Call on Friday, November 8th at 8:30 a.m. Eastern time
November 04 2013 - 8:00AM
Business Wire
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the
Company), the developer of a novel technology for the sustained
production and delivery of therapeutic proteins in patients using
their own tissue, announces that the Company will host an
investment community conference call on Friday, November 8, 2013
beginning at 8:30 a.m. Eastern time to provide a business update
and to answer questions. Shareholders and other interested parties
may participate in the conference call by dialing 877-664-6134
(from within the U.S.) or 702-495-1913 (from outside the U.S.) or
1-809-457-877 (toll-free from Israel) and entering passcode
94707205. The call also will be broadcast live on the Internet at
www.streetevents.com, www.earnings.com and www.medgenics.com.
A replay of the conference call will be accessible two hours
after its completion through November 14, 2013 by dialing (855)
859-2056 (from within the U.S.) or (404) 537-3406 (from outside the
U.S.) and entering passcode 94707205. The call will also be
archived for 90 days at www.streetevents.com, www.earnings.com and www.medgenics.com.
About Medgenics
Medgenics is developing and commercializing Biopump™, a
proprietary tissue-based platform technology for the sustained
production and delivery of therapeutic proteins using the patient's
own tissue for the treatment of a range of chronic diseases
including anemia, hepatitis, among others. For more information,
please visit www.medgenics.com.
Forward-looking Statements This release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act
of 1934 and as that term is defined in the Private Securities
Litigation Reform Act of 1995, which include all statements other
than statements of historical fact, including (without limitation)
those regarding the Company's financial position, its development
and business strategy, its product candidates and the plans and
objectives of management for future operations. The Company intends
that such forward-looking statements be subject to the safe harbors
created by such laws. Forward-looking statements are sometimes
identified by their use of the terms and phrases such as
"estimate," "project," "intend," "forecast," "anticipate," "plan,"
"planning, "expect," "believe," "will," "will likely," "should,"
"could," "would," "may" or the negative of such terms and other
comparable terminology. All such forward-looking statements are
based on current expectations and are subject to risks and
uncertainties. Should any of these risks or uncertainties
materialize, or should any of the Company's assumptions prove
incorrect, actual results may differ materially from those included
within these forward-looking statements. Accordingly, no undue
reliance should be placed on these forward-looking statements,
which speak only as of the date made. The Company expressly
disclaims any obligation or undertaking to disseminate any updates
or revisions to any forward-looking statements contained herein to
reflect any change in the Company's expectations with regard
thereto or any change in events, conditions or circumstances on
which any such statements are based. As a result of these factors,
the events described in the forward-looking statements contained in
this release may not occur.
Medgenics, Inc.John Leaman,
CFOjohn.leaman@medgenics.comorLHAAnne Marie Fields,
212-838-3777afields@lhai.com@LHA_IR_PRorAbchurch CommunicationsAdam
Michael/Joanne Shears/Jamie Hooper+44 207 398
7719jamie.hooper@abchurch-group.comorOriel Securities (NOMAD &
Joint Broker)Jonathan Senior/Giles Balleny+44 207710 7617orSVS
Securities plc (Joint Broker)Alex Brearley+44 207 638-5600
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Oct 2023 to Oct 2024